Payment overview · 2025
General Payments
$306.65
17 reported records · 7 companies
Healthcare provider profile · identity verified
Steven Mark Ramsaran, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAWRENCEVILLE, IL · NPI 1538134416
Verified facts
What the public records show
CMS Open Payments records show Steven Mark Ramsaran, M.D. received $306.65 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $80.84 | 26.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.04 | 22.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.12 | 19.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.30 | 12.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.33 | 9.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.02 | 5.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.00 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $306.65 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $80.84 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $60.12 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.12 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $46.47 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.59 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.59 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 109 |
| Lisinopril | Lisinopril | 345 | 82 |
| Gabapentin | Gabapentin | 312 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 56 |
| Furosemide | Furosemide | 292 | 55 |
| Montelukast Sodium | Montelukast Sodium | 273 | 57 |
| Carvedilol | Carvedilol | 264 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 258 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 49 |
| Famotidine | Famotidine | 223 | 49 |
| Potassium Chloride | Potassium Chloride | 221 | 54 |
| Tramadol Hcl | Tramadol Hcl | 187 | 45 |
| Alprazolam | Alprazolam | 173 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 39 |
| Omeprazole | Omeprazole | 166 | 33 |
| Prednisone | Prednisone | 153 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 136 | 23 |
| Allopurinol | Allopurinol | 124 | 23 |
| Alendronate Sodium | Alendronate Sodium | 110 | 27 |
| Eliquis | Apixaban | 103 | 17 |
| Warfarin Sodium | Warfarin Sodium | 102 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 98 | 18 |
| Sertraline Hcl | Sertraline Hcl | 97 | 17 |
| Ezetimibe | Ezetimibe | 92 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 20 |
| Jardiance | Empagliflozin | 88 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 14 |
| Sucralfate | Sucralfate | 83 | 15 |
| Simvastatin | Simvastatin | 82 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 22 |
| Losartan Potassium | Losartan Potassium | 74 | 19 |
| Memantine Hcl | Memantine Hcl | 74 | 16 |
| Metformin Hcl | Metformin Hcl | 74 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 22 |
| Fenofibrate | Fenofibrate | 66 | 16 |
| Trazodone Hcl | Trazodone Hcl | 66 | 14 |
| Buspirone Hcl | Buspirone Hcl | 62 | 11 |
| Cephalexin | Cephalexin | 62 | 46 |
| Glimepiride | Glimepiride | 62 | 16 |
| Spironolactone | Spironolactone | 60 | 12 |
| Donepezil Hcl | Donepezil Hcl | 58 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 17 |
| Tradjenta | Linagliptin | 56 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 54 | 24 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Repatha Sureclick | Evolocumab | 51 | suppressed |
| Pregabalin | Pregabalin | 50 | suppressed |
| Finasteride | Finasteride | 49 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 11 |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Rybelsus | Semaglutide | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 14 |
| Kerendia | Finerenone | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Metolazone | Metolazone | 40 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Nystatin | Nystatin | 39 | 18 |
| Amoxicillin | Amoxicillin | 38 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Irbesartan | Irbesartan | 38 | 11 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 34 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 34 | 22 |
| Repatha Syringe | Evolocumab | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 20 |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 12 |
| Linzess | Linaclotide | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $306.65 · 17 records | Amgen Inc. | JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, REPATHA, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error